<p>根据 Candriam S.C.A.最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第三季度将其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免费报告）的持股比例提高了 46.9%。该机构投资者在此期间额外购买了 399,273 股后，持有该公司 1,249,727 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Candriam S.C.A.持有 Olema Pharmaceuticals 的股份占比为 1.82%，价值为 12,235,000 美元。</p>
<p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些对冲基金和机构投资者也对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度新购入了价值 172,000 美元的 Olema Pharmaceuticals 股票。高盛集团在第一季度将其在 Olema Pharmaceuticals 的持股比例提高了 93.6%。高盛集团目前持有 741,329 股该公司的股票，价值为 2,787,000 美元，此前在此期间又购买了 358,412 股。Jane Street Group LLC 在第一季度将其在 Olema Pharmaceuticals 的持股增加了 216.8%。Jane Street Group LLC 目前持有 138,552 股该公司的股票，价值为 521,000 美元，此前在上个季度又购买了 94,815 股。FNY Investment Advisers LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 目前持有 10,000 股该公司的股票，价值为 42,000 美元，此前在上个季度又购买了 5,000 股。最后，ProShare Advisors LLC 在第二季度将其在 Olema Pharmaceuticals 的持股提高了 21.1%。ProShare Advisors LLC 目前持有 14,766 股该公司的股票，价值为 63,000 美元，此前在上个季度又购买了 2,569 股。机构投资者和对冲基金持有该公司 91.78% 的股份。</p>
<h2>Olema Pharmaceuticals 股票表现</h2>
<p>周三，OLMA 股票开盘价为 23.37 美元。该股票的 50 日简单移动平均线为 27.30 美元，200 日简单移动平均线为 15.91 美元。该公司的流动比率为 8.03，速动比率为 8.03，债务与股本比率为 0.01。Olema Pharmaceuticals, Inc.的 12 个月最低价为 2.86 美元，最高价为 36.26 美元。该公司的市值为 16 亿美元，市盈率为-12.50，贝塔值为 1.89。</p>
<p>Olema Pharmaceuticals（NASDAQ:OLMA - 获取免费报告）最近于 11 月 10 日发布了季度财报。该公司报告季度每股收益为（0.49 美元），低于市场共识预期的（0.44 美元）0.05 美元。整体来看，股票研究分析师预测 Olema Pharmaceuticals, Inc.在本年度将发布-2.33 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>OLMA 已成为多份研究报告的主题。高盛集团在 12 月 11 日的研究报告中将 Olema Pharmaceuticals 的目标价从 26.00 美元上调至 38.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Olema Pharmaceuticals 股票的 “卖出（d-）” 评级。Oppenheimer 在 12 月 11 日的研究报告中将 Olema Pharmaceuticals 的目标价从 45.00 美元上调至 48.00 美元，并给予该股票 “跑赢大盘” 评级。HC Wainwright 在 12 月 11 日的报告中将 Olema Pharmaceuticals 的目标价从 36.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。最后，瑞银集团在 1 月 7 日的研究报告中开始覆盖 Olema Pharmaceuticals。他们对该股票设定了 “买入” 评级和 45.00 美元的目标价。八位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Olema Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 41.00 美元。</p>
<p><strong>查看我们关于 OLMA 的最新报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，董事 Cyrus Harmon 于 1 月 20 日星期二出售了 10,000 股该股票，交易平均价格为 26.88 美元，总价值为 268,800.00 美元。交易完成后，该董事持有 727,770 股该公司的股票，价值约为 19,562,457.60 美元。这代表其持股比例减少了 1.36%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，内部人士 Shane William Charles Kovacs 于 1 月 15 日星期四出售了 100,000 股 Olema Pharmaceuticals 股票。该股票的平均售价为 28.73 美元，总交易额为 2,873,000.00 美元。出售后，该内部人士持有 139,727 股该公司的股票，价值约为 4,014,356.71 美元。这代表其持股比例减少了 41.71%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 765,501 股公司股票，价值为 22,052,432 美元。16.36% 的股票由内部人士持有。</p>
<h2>Olema Pharmaceuticals 简介</h2>
<p>（免费报告）</p>
<p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症的治疗方法的发现、开发和商业化。其主要产品候选药物是 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的一期/二期临床试验，针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 Olema Pharmaceuticals</li>
<li>Nvidia CEO 发出大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
<p><strong>想看看其他对 OLMA 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
<p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Olema Pharmaceuticals 并不在名单上。</p>
<p>虽然 Olema Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OLMA

<p>Candriam S.C.A. 在第三季度将其在 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) 的持股增加了 46.9%，目前拥有 1,249,727 股，价值 1,224 万美元。其他机构投资者也调整了他们的持仓，高盛和简街集团的增持幅度显著。Olema 的股票开盘价为 23.37 美元，市值为 16 亿美元。分析师的评级意见不一，平均目标价共识为 41.00 美元。最近有内部人士出售股票的报告，包括一名董事出售了 10,000 股</p>

<p>Candriam S.C.A. raised its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 46.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,249,727 shares of the company's stock after acquiring an additional 399,273 shares during the period. Candriam S.C.A. owned 1.82% of Olema Pharmaceuticals worth $12,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据 Candriam S.C.A.最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第三季度将其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免费报告）的持股比例提高了 46.9%。该机构投资者在此期间额外购买了 399,273 股后，持有该公司 1,249,727 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Candriam S.C.A.持有 Olema Pharmaceuticals 的股份占比为 1.82%，价值为 12,235,000 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Olema Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC acquired a new position in shares of Olema Pharmaceuticals in the 1st quarter valued at $172,000. Goldman Sachs Group Inc. grew its stake in shares of Olema Pharmaceuticals by 93.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company's stock worth $2,787,000 after purchasing an additional 358,412 shares during the period. Jane Street Group LLC increased its holdings in Olema Pharmaceuticals by 216.8% in the first quarter. Jane Street Group LLC now owns 138,552 shares of the company's stock valued at $521,000 after buying an additional 94,815 shares in the last quarter. FNY Investment Advisers LLC increased its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock valued at $42,000 after purchasing an additional 5,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Olema Pharmaceuticals by 21.1% during the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company's stock worth $63,000 after buying an additional 2,569 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也对该公司的持仓进行了调整。AQR Capital Management LLC 在第一季度新购入了价值 172,000 美元的 Olema Pharmaceuticals 股票。高盛集团在第一季度将其在 Olema Pharmaceuticals 的持股比例提高了 93.6%。高盛集团目前持有 741,329 股该公司的股票，价值为 2,787,000 美元，此前在此期间又购买了 358,412 股。Jane Street Group LLC 在第一季度将其在 Olema Pharmaceuticals 的持股增加了 216.8%。Jane Street Group LLC 目前持有 138,552 股该公司的股票，价值为 521,000 美元，此前在上个季度又购买了 94,815 股。FNY Investment Advisers LLC 在第二季度将其在 Olema Pharmaceuticals 的持股增加了 100.0%。FNY Investment Advisers LLC 目前持有 10,000 股该公司的股票，价值为 42,000 美元，此前在上个季度又购买了 5,000 股。最后，ProShare Advisors LLC 在第二季度将其在 Olema Pharmaceuticals 的持股提高了 21.1%。ProShare Advisors LLC 目前持有 14,766 股该公司的股票，价值为 63,000 美元，此前在上个季度又购买了 2,569 股。机构投资者和对冲基金持有该公司 91.78% 的股份。</p>
</div><h2>Olema Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票表现</h2>
</div><p>OLMA stock opened at $23.37 on Wednesday. The stock's 50 day simple moving average is $27.30 and its 200 day simple moving average is $15.91. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26. The firm has a market cap of $1.60 billion, a P/E ratio of -12.50 and a beta of 1.89.</p>
<div class="lb-trans"><p>周三，OLMA 股票开盘价为 23.37 美元。该股票的 50 日简单移动平均线为 27.30 美元，200 日简单移动平均线为 15.91 美元。该公司的流动比率为 8.03，速动比率为 8.03，债务与股本比率为 0.01。Olema Pharmaceuticals, Inc.的 12 个月最低价为 2.86 美元，最高价为 36.26 美元。该公司的市值为 16 亿美元，市盈率为-12.50，贝塔值为 1.89。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, equities research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（NASDAQ:OLMA - 获取免费报告）最近于 11 月 10 日发布了季度财报。该公司报告季度每股收益为（0.49 美元），低于市场共识预期的（0.44 美元）0.05 美元。整体来看，股票研究分析师预测 Olema Pharmaceuticals, Inc.在本年度将发布-2.33 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>OLMA has been the subject of several research reports. The Goldman Sachs Group lifted their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Oppenheimer increased their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, December 11th. HC Wainwright raised their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. Finally, UBS Group initiated coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $45.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Olema Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $41.00.</p>
<div class="lb-trans"><p>OLMA 已成为多份研究报告的主题。高盛集团在 12 月 11 日的研究报告中将 Olema Pharmaceuticals 的目标价从 26.00 美元上调至 38.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Olema Pharmaceuticals 股票的 “卖出（d-）” 评级。Oppenheimer 在 12 月 11 日的研究报告中将 Olema Pharmaceuticals 的目标价从 45.00 美元上调至 48.00 美元，并给予该股票 “跑赢大盘” 评级。HC Wainwright 在 12 月 11 日的报告中将 Olema Pharmaceuticals 的目标价从 36.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。最后，瑞银集团在 1 月 7 日的研究报告中开始覆盖 Olema Pharmaceuticals。他们对该股票设定了 “买入” 评级和 45.00 美元的目标价。八位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Olema Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 41.00 美元。</p>
</div><p><strong>View Our Latest Report on OLMA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 OLMA 的最新报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total value of $268,800.00. Following the completion of the transaction, the director owned 727,770 shares of the company's stock, valued at approximately $19,562,457.60. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $28.73, for a total transaction of $2,873,000.00. Following the sale, the insider owned 139,727 shares in the company, valued at approximately $4,014,356.71. This represents a 41.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 765,501 shares of company stock valued at $22,052,432 in the last quarter. 16.36% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Cyrus Harmon 于 1 月 20 日星期二出售了 10,000 股该股票，交易平均价格为 26.88 美元，总价值为 268,800.00 美元。交易完成后，该董事持有 727,770 股该公司的股票，价值约为 19,562,457.60 美元。这代表其持股比例减少了 1.36%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，内部人士 Shane William Charles Kovacs 于 1 月 15 日星期四出售了 100,000 股 Olema Pharmaceuticals 股票。该股票的平均售价为 28.73 美元，总交易额为 2,873,000.00 美元。出售后，该内部人士持有 139,727 股该公司的股票，价值约为 4,014,356.71 美元。这代表其持股比例减少了 41.71%。该销售的 SEC 文件提供了更多信息。内部人士在上个季度出售了 765,501 股公司股票，价值为 22,052,432 美元。16.36% 的股票由内部人士持有。</p>
</div><h2>Olema Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于女性癌症的治疗方法的发现、开发和商业化。其主要产品候选药物是 OP-1250，一种雌激素受体（ER）拮抗剂和选择性 ER 降解剂，目前正在进行针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌的三期临床试验；以及 OP-1250 与 CDK4/6 抑制剂 palbociclib、ribociclib 和 alpelisib 联合进行的一期/二期临床试验，针对复发性、局部晚期或转移性雌激素受体阳性、HER2 阴性乳腺癌，同时开发 OPERA-01 用于 ER+/HER2-晚期或转移性乳腺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>The day the gold market broke</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Olema Pharmaceuticals</li>
<li>Nvidia CEO 发出大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>黄金市场崩溃的那一天</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OLMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 OLMA 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OLMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Olema Pharmaceuticals 吗？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Olema Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而 Olema Pharmaceuticals 并不在名单上。</p>
</div><p>While Olema Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Olema Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Candriam S.C.A. 增持了 Olema Pharmaceuticals, Inc. 的股票头寸 $OLMA